AHPA keeps members and the industry informed of recent news and developments that impact the trade through email alerts. Subscribe to news as it happens or a weekly summary of all alerts.
View recent alerts:
Subscribe to AHPA Updates to stay informed about the latest AHPA news and resources.
Published: Friday, December 11, 2015
Editor's Note: This limited study assessed the effect of resveratrol on the pharmacokinetics of diclofenac, the nonsteroidal anti-inflammatory drug, in 12 healthy human volunteers. Resveratrol significantly enhanced maximum plasma concentration, area under the curve, half-life, decreased elimination rate constant, and apparent oral clearance of diclofenac compared to control. The authors suggested that the altered pharmacokinetics might be attributed to resveratrol mediated inhibition of CYP2C9 enzyme.
December 3, 2015
The purpose of the present study was to assess the effect of resveratrol (RSV) treatment on the pharmacokinetics of diclofenac (DIC) in healthy human volunteers. The open-label, two period, sequential study was conducted in 12 healthy human volunteers. A single dose of RSV 500 mg was administered daily for 10 days during treatment phase. A single dose of DIC 100 mg was administered during control and after treatment phases under fasting conditions. The blood samples were collected after DIC dosing and analyzed by HPLC. Treatment with RSV significantly enhanced maximum plasma concentration (Cmax) (1.73 to 2.91 µg/mL), area under the curve (AUC) (5.05 to 9.95 µg h/mL), half life (T1/2) (1.12 to 1.76 h) and significantly decreased elimination rate constant (Kel) (0.71 to 0.41 h−1), apparent oral clearance (CL/F) (14.58 to 6.48 L/h) of DIC as compared to control. The geometric mean ratios for Cmax, AUC, T1/2, Kel and CL/F of DIC were 1.75, 2.12, 1.65, 0.61 and 0.47, respectively were outside the limits of 0.8–1.25, which indicates clinically significant interaction between DIC and RSV. The results suggest that the altered pharmacokinetics of DIC might be attributed to RSV mediated inhibition of CYP2C9 enzyme. Therefore, combination therapy of DIC along with RSV may represent a novel approach to reduce dosage and results in reduced gastrointestinal side effects of DIC.
Click on these links to see a filtered list of alerts in one of these four topic areas
2019 Annual Fund Sponsors
AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.